https://majorhealthnews.com/press-releases/amgen-announces-positive-phase-3-results-for-dazodalibep-in-sjogrens-diseaseMajor Health Newsen2026-11-11T13:13:57.122ZAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE https://majorhealthnews.com/press-releases/context-therapeutics-reports-third-quarter-2026-financial-results-and-pipeline-progressMajor Health Newsen2026-11-10T21:39:35.141ZContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress https://majorhealthnews.com/press-releases/dominari-reports-q3-2026-resultsMajor Health Newsen2026-11-10T13:08:35.627ZDominari Reports Q3 2026 Results https://majorhealthnews.com/press-releases/city-therapeutics-announces-first-participant-dosed-in-phase-1-clinical-trial-of-cityMajor Health Newsen2026-11-10T12:31:05.750ZCity Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease https://majorhealthnews.com/press-releases/cullinan-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financialMajor Health Newsen2026-11-10T12:20:22.715ZCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://majorhealthnews.com/press-releases/ovid-therapeutics-reports-business-updates-and-third-quarter-2026-financial-resultsMajor Health Newsen2026-11-10T12:20:05.627ZOvid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results https://majorhealthnews.com/press-releases/black-diamond-therapeutics-announces-positive-updated-silevertinib-phase-2-results-fdaMajor Health Newsen2026-11-10T11:49:31.997ZBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update https://majorhealthnews.com/press-releases/lipocine-doses-first-participant-in-bloom-phase-3-study-of-lpcn-1154-for-postpartumMajor Health Newsen2026-11-10T11:31:31.326ZLipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression